Evolving tariff/trade policy, US drug pricing reforms, and a changing global landscape are contributing to an uncertain environment. A DCAT Week education program, featuring experts from IQVIA, will provide in-depth insights on pharma industry performance. 

Tracking pharmaceutical industry performance
Last year (2025) was certainly a year of change for the bio/pharmaceutical industry, which was confronted with new variables to factor into the calculus of business strategies. A fluid US tariff/trade scheme, leadership changes and policy resets at the US Food and Drug Administration and other regulatory bodies, and US drug pricing reforms in the form of moves to most-favored-nation drug pricing were among the large-ticket items facing the industry. At the same time, policymakers in the European Union (EU) took significant steps in advancing major reforms to the EU’s regulatory framework, representing the most significant overhaul of the regulatory framework of pharmaceuticals in the EU in over two decades, with the goal of increasing competitiveness, innovation, and security of medicines supply. In addition, a changing geopolitical landscape raised further questions globally, including the role that China, the second largest pharmaceutical market worldwide, will play in the direction of the industry.

The bottom-line questions are what has been the impact on the performance of the bio/pharmaceutical industry, and what may be in store? How did the industry perform in 2025, and what can be expected in 2026 and beyond? To answer those all-important questions, the Pharma Industry Outlook education program at DCAT Week will provide valuable insights from leading experts at IQVIA, regarded as the gold standard for business intelligence for the global bio/pharmaceutical industry. Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, will provide the latest market data, analysis, and trends on:

• Overall market growth on a value and volume basis;
• Growth prospects for innovator and generics/biosimilars;
• Leading therapeutic sectors: pipelines and commercial products;
• Market share and growth rates for the major developed markets: the United States, the European Union, the UK, and Japan.
• An outlook for emerging markets, including China and India.

In addition, Murray Aitken, Senior Vice President, IQVIA and Executive Director, The IQVIA Institute for Human Data Science, will provide further insight on the impact on R&D and commercialization strategies.

The Pharma Industry Outlook program is part of DCAT Week, the premier gathering for companies engaged in the global bio/pharmaceutical business ecosystem, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week will be held March 23–26, 2026, in New York. The Pharma Industry Outlook program will be held on Monday March 23, 2026, 3:00 to 4:30 PM, followed by a post-program networking reception from 4:30 to 6:00 PM. Further information, including how to register, may be found here.